{
    "root": "96765b43-a41f-4bba-a582-0e130e813ad3",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "Human Prescription Drug Label",
    "name": {
        "text": "Paliperidone"
    },
    "value": "20250221",
    "ingredients": [
        {
            "name": "PALIPERIDONE",
            "code": "838F01T721"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POVIDONE K30",
            "code": "U725QWY32X"
        },
        {
            "name": "BUTYLATED HYDROXYTOLUENE",
            "code": "1P9D0Z171K"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE, UNSPECIFIED",
            "code": "9XZ8H6N6OH"
        },
        {
            "name": "CELLULOSE ACETATE",
            "code": "3J2P07GVB6"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        }
    ],
    "indications": "paliperidone extended-release tablets atypical antipsychotic agent indicated treatment schizophrenia ( 1.1 ) adults : efficacy established three 6-week trials one maintenance trial . ( 14.1 ) adolescents ( ages 12 17 ) : efficacy established one 6-week trial . ( 14.1 ) treatment schizoaffective disorder monotherapy adjunct mood stabilizers and/or antidepressants . ( 1.2 ) efficacy established two 6-week trials adult patients . ( 14.2 )",
    "contraindications": "initial dose recommended dose maximum dose schizophrenia - adults ( 2.1 ) 6 mg/day 3 12 mg/day 12 mg/day schizophrenia - adolescents ( 2.1 ) weight < 51 kg 3 mg/day 3 6 mg/day 6 mg/day weight ≥ 51kg 3 mg/day 3 12 mg/day 12 mg/day schizoaffective disorder - adults ( 2.2 ) 6 mg/day 3 12 mg/day 12 mg/day tablet swallowed whole chewed , divided , crushed . ( 2.3 )",
    "warningsAndPrecautions": "paliperidone extended-release tablets available following strengths packages . tablets round-shaped . 1.5 mg tablets brown colored , round , biconvex , film-coated tablet release portal one side ‘ pl1 ’ imprinting black ink either side tablets , available bottles 30 child resistant closure ( ndc 27241-276-30 ) . 3 mg tablets white off-white colored , round , biconvex , film-coated tablet release portal one side ‘ pl2 ’ imprinting black ink either side tablets , available bottles 30 child resistant closure ( ndc 27241-277-30 ) 6 mg tablets yellow colored , round , biconvex , film-coated tablet release portal one side ‘ pl3 ’ imprinting black ink either side tablets , available bottles 30 child resistant closure ( ndc 27241-278-30 ) 9 mg tablets pink colored , round , biconvex , film-coated tablet release portal one side ‘ pl4 ’ imprinting black ink either side tablets , available bottles 30 child resistant closure ( ndc 27241-279-30 ) . storage handling store 20°c 25°c ( 68°f 77°f ) ; excursions permitted 15°c 30°c ( 59°f 86°f ) [ usp controlled room temperature ] . protect moisture . keep reach children .",
    "adverseReactions": "paliperidone contraindicated patients known hypersensitivity either paliperidone risperidone , excipients paliperidone formulation . hypersensitivity , including anaphylactic angioedema , reported patients treated risperidone patients treated paliperidone . paliperidone metabolite risperidone .",
    "indications_original": "Paliperidone extended-release tablets are an atypical antipsychotic agent indicated for Treatment of schizophrenia ( 1.1 ) Adults: Efficacy was established in three 6-week trials and one maintenance trial. ( 14.1 ) Adolescents (ages 12 to 17): Efficacy was established in one 6-week trial. ( 14.1 ) Treatment of schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers and/or antidepressants. ( 1.2 ) Efficacy was established in two 6-week trials in adult patients. ( 14.2 )",
    "contraindications_original": "Initial Dose Recommended Dose Maximum Dose Schizophrenia - adults ( 2.1 ) 6 mg/day 3 to 12 mg/day 12 mg/day Schizophrenia - adolescents ( 2.1 ) Weight < 51 kg 3 mg/day 3 to 6 mg/day 6 mg/day Weight ≥ 51kg 3 mg/day 3 to 12 mg/day 12 mg/day Schizoaffective disorder - adults ( 2.2 ) 6 mg/day 3 to 12 mg/day 12 mg/day Tablet should be swallowed whole and should not be chewed, divided, or crushed. ( 2.3 )",
    "warningsAndPrecautions_original": "Paliperidone extended-release tablets are available in the following strengths and packages. All tablets are round-shaped.\n                  \n                  1.5 mg tablets are brown colored, round, biconvex, film-coated tablet with release portal on one side and ‘PL1’ imprinting with black ink on either side of the tablets, and are available in \n                  Bottles of 30 with child resistant closure                        (NDC 27241-276-30).\n                  \n                  3 mg tablets are white to off-white colored, round, biconvex, film-coated tablet with release portal on one side and ‘PL2’ imprinting with black ink on either side of the tablets, and are available in \n                  Bottles of 30 with child resistant closure                        (NDC 27241-277-30)\n                  \n                  6 mg tablets are yellow colored, round, biconvex, film-coated tablet with release portal on one side and ‘PL3’ imprinting with black ink on either side of the tablets, and are available in \n                  Bottles of 30 with child resistant closure                        (NDC 27241-278-30)\n                  \n                  9 mg tablets are pink colored, round, biconvex, film-coated tablet with release portal on one side and ‘PL4’ imprinting with black ink on either side of the tablets, and are available in \n                  Bottles of 30 with child resistant closure                        (NDC 27241-279-30).\n                  \n                      \n                  \n                  \n                     Storage and Handling\n                  \n                  Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Protect from moisture.\n                  \n                   Keep out of reach of children.",
    "adverseReactions_original": "Paliperidone is contraindicated in patients with a known hypersensitivity to either paliperidone or risperidone, or to any of the excipients in the paliperidone formulation. Hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported in patients treated with risperidone and in patients treated with paliperidone. Paliperidone is a metabolite of risperidone."
}